Serum potassium levels on admission and infarct size in patients with acute myocardial infarction

Clinica Chimica Acta

Volumn 409, Issue 1-2, 2009, Pages 46-51

  Roos, Marcel ^a   Ndrepepa, Gjin ^b   Baumann, Marcus ^a   Pan, Cheng Rui ^a   Heemann, Uwe ^a   Lutz, Jens ^a   Keta, Dritan ^b   Schulz, Stefanie ^b   Byrne, Robert A ^b   Mehilli, Julinda ^b   Schömig, Albert ^b   Kastrati, Adnan ^b  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Infarct size; Myocardial infarction; Potassium; SPECT imaging

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; POTASSIUM; TICLOPIDINE;

ACUTE HEART INFARCTION; ADULT; ARTICLE; BARE METAL STENT; CONTROLLED STUDY; CORONARY STENT; FEMALE; HEART INFARCTION SIZE; HOSPITAL ADMISSION; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; POTASSIUM BLOOD LEVEL; PREDICTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

FEMALE; HUMANS; MIDDLE AGED; MULTIVARIATE ANALYSIS; MYOCARDIAL INFARCTION; PATIENT ADMISSION; POTASSIUM; RETROSPECTIVE STUDIES; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 70349992410     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cca.2009.08.014     Document Type: Article

References (40)

1. Miller T.D., Christian T.F., Hopfenspirger M.R., Hodge D.O., Gersh B.J., and Gibbons R.J. Infarct size after acute myocardial infarction measured by quantitative tomographic 99mTc sestamibi imaging predicts subsequent mortality. Circulation 92 (1995) 334-341
2. Burns R.J., Gibbons R.J., Yi Q., et al. CORE Study Investigators. The relationships of left ventricular ejection fraction, end-systolic volume index and infarct size to six-month mortality after hospital discharge following myocardial infarction treated by thrombolysis. J Am Coll Cardiol 39 (2002) 30-36
3. Gibbons R.J., Valeti U.S., Araoz P.A., and Jaffe A.S. The quantification of infarct size. J Am Coll Cardiol 44 (2004) 1533-1542
4. Schömig A., Kastrati A., Dirschinger J., et al. Coronary stenting plus platelet glycoprotein IIb/IIIa blockade compared with tissue plasminogen activator in acute myocardial infarction: stent versus thrombolysis for occluded coronary arteries in patients with acute myocardial infarction study investigators. N Engl J Med 343 (2000) 385-391
5. Kloner R.A., Rezkalla S.H. Cardiac protection during acute myocardial infarction: where do we stand in 2004? J Am Coll Cardiol 2004;44:276-86. Review.
6. Hammerman H., Kloner R.A., Briggs L.L., and Braunwald E. Enhancement of salvage of reperfused myocardium by early beta-adrenergic blockade (timolol). J Am Coll Cardiol 3 (1984) 1438-1443
7. Gross G.J., and Peart J.N. K-ATP channels and myocardial preconditioning: an update. Am J Physiol Heart Circ Physiol 285 (2003) H921-H930
8. Sasaki N., Murata M., Guo Y., et al. MCC-134, a single pharmacophore, opens surface ATP-sensitive potassium channels, blocks mitochondrial ATP-sensitive potassium channels, and suppresses preconditioning. Circulation 107 (2003) 1183-1188
9. Tsuchida A., Miura T., Tanno M., et al. Infarct size limitation by nicorandil: roles of mitochondrial K(ATP) channels, sarcolemmal K(ATP) channels, and protein kinase C. J Am Coll Cardiol 40 (2002) 1523-1530
10. Wannamethee S.G., Lever A.F., Shaper A.G., and Whincup P.H. Serum potassium, cigarette smoking, and mortality in middle-aged men. Am J Epidemiol 145 (1997) 598-606
11. Kaplan N.M. Our appropriate concern about hypokalemia. Am J Med 77 (1984) 1-4
12. Schulman M., and Narins R.G. Hypokalemia and cardiovascular disease. Am J Cardiol 65 (1990) 4E-9E
13. Hoes A.W., Grobbee D.E., Peet T.M., and Lubsen J. Do non-potassiumsparing diuretics increase the risk of sudden cardiac death in hypertensive patients? Recent evidence. Drugs 47 (1994) 711-733
14. Dorrance A.M., Pollock D.M., Romanko O.P., and Stepp D.W. A high-potassium diet reduces infarct size and improves vascular structure in hypertensive rats. Am J Physiol Regul Integr Comp Physiol 292 (2007) R415-R422
15. Ndrepepa G., Mehilli J., Martinoff S., Schwaiger M., Schömig A., and Kastrati A. Evolution of left ventricular ejection fraction and its relationship to infarct size after acute myocardial infarction. J Am Coll Cardiol 50 (2007) 149-156
16. Srivastava T.N., and Young D.B. Impairment of cardiac function by moderate potassium depletion. J Card Fail 1 (1995) 195-200
17. Taddei S., Mattei P., Virdis A., Sudano I., Ghiadoni L., and Salvetti A. Effect of potassium on vasodilation to acetylcholine in essential hypertension. Hypertension 23 (1994) 485-490
18. Raij L., Luscher T.F., and Vanhoutte P.M. High potassium diet augments endothelium-dependent relaxations in the Dahl rat. Hypertension 12 (1988) 562-567
19. Young D.B., Lin H., and McCabe R.D. Potassium's cardiovascular protective mechanisms. Am J Physiol 268 (1995) R825-R837
20. Appel L.J., Moore T.J., Obarzanek E., et al. A clinical trial of the effects of dietary patterns on blood pressure: DASH collaborative research group. N Engl J Med 336 (1997) 1117-1124
21. Madias J.E., Shah B., Chintalapally G., Chalavarya G., and Madias N.E. Admission serum potassium in patients with acute myocardial infarction: its correlates and value as a determinant of in-hospital outcome. Chest 118 (2000) 904-913
22. Obeid A.I., Verrier R.L., and Lown B. Influence of glucose, insulin, and potassium on vulnerability to ventricular fibrillation in the canine heart. Circ Res 43 (1978) 601-608
23. Grover G.J., and Garlid K.D. ATP-sensitive potassium channels: a review of their cardioprotective pharmacology. J Mol Cell Cardiol 32 (2000) 677-695
24. Genda S., Miura T., Miki T., Ichikawa Y., and Shimamoto K. K(ATP) channel opening is an endogenous mechanism of protection against the no-reflow phenomenon but its function is compromised by hypercholesterolemia. J Am Coll Cardiol 40 (2002) 1339-1346
25. Murry C.E., Jennings R.B., and Reimer K.A. Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. Circulation 74 (1986) 1124-1136
26. Ito H., Maruyama A., Iwakura K., et al. Clinical implications of the 'no reflow' phenomenon. A predictor of complications and left ventricular remodeling in reperfused anterior wall myocardial infarction. Circulation 93 (1996) 223-228
27. Tsuchida A., Miura T., Tanno M., et al. Infarct size limitation by nicorandil: roles of mitochondrial K(ATP) channels, sarcolemmal K(ATP) channels, and protein kinase C. J Am Coll Cardiol 40 (2002) 1523-1530
28. Pasdois P., Beauvoit B., Costa A.D., et al. Sarcoplasmic ATP-sensitive potassium channel blocker HMR1098 protects the ischemic heart: implication of calcium, complex I, reactive oxygen species and mitochondrial ATP-sensitive potassium channel. J Mol Cell Cardiol 42 (2007) 631-642
29. Oliver M.F., and Opie L.H. Effects of glucose and fatty acids on myocardial ischemia and arrhythmias. Lancet 343 (1994) 155-158
30. Opie L.H., Tansey M., and Kennelly B.M. Proposed metabolic vicious circle in patients with large myocardial infarction and high plasma free fatty acid concentrations. Lancet 2 (1977) 890-892
31. Oliver M.F., Kurien V.A., and Greenwood T.W. Relation between serum free fatty acids and arrhythmias and death after acute myocardial infarction. Lancet 1 (1968) 710-714
32. Apstein C.S., and Tacgtmeyer H. Glucose-insulin-potassium in acute myocardial infarction: the time has come for a large, prospective trial. Circulation 96 (1997) 1074-1077
33. Cave A.C., Ingwall J.S., Friedrich J., Liao R., Saupe K.W., and Apstein C.S. ATP synthesis during low-flow ischemia: influence of increased glycolytic substrate. Circulation 101 (2000) 2090-2094
34. Murcia A.M., Hennekens C.H., Lamas G.A., et al. Impact of diabetes on mortality in patients with myocardial infarction and left ventricular dysfunction. Arch Intern Med 164 (2004) 2273-2279
35. Klamann A., Sarfert P., Launhardt V., Schulte G., Schmiegel W.H., and Nauck M.A. Myocardial infarction in diabetic vs non-diabetic subjects. Survival and infarct size following therapy with sulfonylureas (glibencl mide). Eur Heart J 21 (2000) 220-229
36. Fath-Ordoubadi F., and Beatt K.J. Glucose-insulin-potassium therapy for treatment of acute myocardial infarction: an overview of randomized placebo-controlled trials. Circulation 96 (1997) 1152-1156
37. van der Horst I.C., Zijlstra F., van 't Hof A.W., et al. Zwolle Infarct Study Group. Glucose-insulin-potassium infusion inpatients treated with primary angioplasty for acute myocardial infarction: the glucose-insulin-potassium study: a randomized trial. J Am Coll Cardiol 42 (2003) 784-791
38. Pache J., Kastrati A., Mehilli J., et al. A randomized evaluation of the effects of glucose-insulin-potassium infusion on myocardial salvage in patients with acute myocardial infarction treated with reperfusion therapy. Am Heart J 148 (2004) e3
39. Díaz R., Paolasso E.A., Piegas L.S., et al. Metabolic modulation of acute myocardial infarction. The ECLA (Estudios Cardiológicos Latinoamérica) Collaborative Group. Circulation 98 (1998) 2227-2234
40. Mehta S.R., Yusuf S., Díaz R., et al. CREATE-ECLA Trial Group Investigators. Effect of glucose-insulin-potassium infusion on mortality in patients with acute ST-segment elevation myocardial infarction: the CREATE-ECLA randomized controlled trial. JAMA 293 (2005) 437-446